Moderna announces Q2 results; crushes earnings
Moderna Inc. announced its Q2 results on Thursday before the bell. 

**Key Highlights:**

* Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates.
* Moderna COVID-19 Vaccine mRNA-1273: Final blinded analysis of Phase 3 COVE study shows 93% efficacy; Efficacy remains durable through six *months after second dose ​*
* Moderna booster candidates demonstrate robust antibody responses to COVID-19 variants of concern in Phase 2
* Dosing started in Phase 1 studies for quadrivalent seasonal flu vaccine candidate (mRNA-1010) and IL-2 mRNA program for autoimmune disorders (mRNA-6231)
* Moderna has mRNA candidates in clinical development across five therapeutic areas: infectious disease, cardiovascular, oncology, rare disease and autoimmune disorders
* **Q2 total revenue of $4.4 billion, net income of $2.8 billion and diluted earnings per share of $6.46**
* Moderna establishes new Charitable Foundation to promote public health, healthcare and educational opportunities, particularly in underserved populations

[https://risingcandle.com/business/moderna-announces-q2-results-crushes-earnings/](https://risingcandle.com/business/moderna-announces-q2-results-crushes-earnings/)
https://www.reddit.com/r/StockMarket/comments/oygb3o/moderna_announces_q2_results_crushes_earnings/